^
Association details:
| Biomarker: | BRAF V600 |
|---|---|
| Cancer: | Thyroid Gland Papillary Carcinoma |
| Drug: | lifirafenib (BGB-283) (EGFR inhibitor, pan-RAF inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Abstract CT002: A Phase IB study of RAF dimer inhibitor BGB-283 in patients with B-RAF or K-RAS/N-RAS mutated solid tumors
Excerpt:
BGB-283 was generally well-tolerated during the Phase 1B stage of the study. Antitumor activity was not only observed in subjects with B-RAF V600-mutated solid tumors including melanoma, PTC, and ovarian cancer, but also in subjects with K-RAS-mutated NSCLC.
DOI:
10.1158/1538-7445.AM2017-CT002
